Ipamorelin

Ipamorelin is a selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist. It binds to the GHS-R1a (growth hormone secretagogue receptor type 1a) to stimulate pulsatile GH release from the anterior pituitary with notable selectivity — producing GH pulses without significantly elevating cortisol, prolactin, or ACTH, which distinguishes it from earlier GHRP compounds.

Ipamorelin is commonly studied alongside GHRH analogs such as CJC-1295 no DAC (Mod-GRF 1-29), as the combination of a GHRH analog and a GHRP is known to produce synergistic GH release through complementary mechanisms at the pituitary level.

• GHS-R1a (ghrelin receptor) binding and activation studies
• Selective pulsatile GH release without cortisol elevation
• Synergistic GH release in combination with GHRH analogs
• Body composition and metabolic research models
• GH axis modulation and IGF-1 production studies
• Comparison with GHRP-2 and GHRP-6 selectivity profiles

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

GH secretagogue. Always fasted. Often combined with CJC-1295 no DAC.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.